Loading
A phase 1 trial of Ipsoprubart run by Electra Therapeutics Inc., now recruiting.
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) is a phase 1 interventional study registered as NCT07465835 by Electra Therapeutics Inc., with 84 participants planned, started 2026-02-17, primary completion expected 2028-06. Conditions recorded: T Cell Malignancies. Interventions recorded: ELA026.
Shares Ipsoprubart, Electra Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/